13.2 Hypertensive Disorders of Pregnancy, Pre-eclampsia, and Eclampsia Management

Key Takeaways

  • New hypertension from 20 weeks with proteinuria, maternal organ dysfunction or uteroplacental dysfunction can indicate pre-eclampsia. It can first present after birth.

  • Assess aspirin eligibility early. Use the selected maternity protocol for the dose and timing.

  • Treat persistent severe BP urgently if systolic is at least 160 or diastolic at least 110 mmHg. Select a pregnancy-compatible agent and monitor the response.

  • Use IV magnesium for eclampsia and indicated prophylaxis. With respiratory depression and suspected toxicity, stop magnesium, support ventilation and give slow IV calcium gluconate.

  • HELLP requires recognition of haemolysis, elevated liver enzymes and low platelets. Stabilise promptly and plan birth and ongoing postpartum monitoring with the specialist team.

Last updated: November 2026

Classify hypertension during pregnancy and after birth

Use a validated pregnancy BP device, the right cuff size and repeat measurements. Hypertension is systolic BP at least 140 mmHg or diastolic BP at least 90 mmHg. If systolic BP is at least 160 or diastolic BP at least 110 mmHg, confirm promptly, usually within 15 minutes under ISSHP guidance, while organising urgent assessment and treatment.

  • Chronic hypertension: Present before pregnancy or identified before 20 weeks. Review baseline kidney function, proteinuria and medication. Persistent hypertension after postpartum reassessment supports chronic disease.
  • Gestational hypertension: New hypertension from 20 weeks without evidence of pre-eclampsia. Reassess for progression, even if the initial urine and blood tests are normal.
  • Pre-eclampsia: New hypertension from 20 weeks with new proteinuria, maternal organ dysfunction or uteroplacental dysfunction. It can first present in labour or after birth.
  • Pre-eclampsia superimposed on chronic hypertension: Look for new organ dysfunction, new proteinuria where baseline protein excretion was normal, or uteroplacental dysfunction. An increase in BP alone is insufficient.

ISSHP classification and assessment · HSE Eclampsia Learning Notice, 2026

Assess the mother and fetus together

Check headache, visual change, epigastric or right upper quadrant pain, breathlessness, reduced urine output and fetal movements. Measure oxygen saturation, take blood for platelets, creatinine and transaminases, and assess fetal status according to gestation. If haemolysis is suspected, add the relevant blood film, bilirubin, LDH and haptoglobin. Discuss growth, amniotic fluid, Doppler and fetal monitoring with the maternity team.

Evidence in a patient with new hypertensionExamples under ISSHP guidance
ProteinuriaSpot protein:creatinine ratio at least 30 mg/mmol or albumin:creatinine ratio at least 8 mg/mmol. A 24-hour result of at least 0.3 g/day can also qualify. Use dipstick 2+ if quantitative assessment is unavailable.
Maternal organ dysfunctionAcute kidney injury, elevated transaminases, falling platelets or thrombocytopenia, haemolysis, DIC, pulmonary oedema, severe neurological symptoms or eclampsia. ISSHP examples include creatinine at least 90 µmol/L, AST or ALT above 40 IU/L and platelets below 150 × 10⁹/L. Trends and the whole picture matter.
Uteroplacental dysfunctionFetal growth restriction, abnormal umbilical artery Doppler, placental abruption or stillbirth. Assess in the clinical context.

A patient can have pre-eclampsia with negative urine protein. Severe headache, persistent visual symptoms, pulmonary oedema, worsening renal or liver tests, falling platelets or fetal compromise require urgent escalation. Where available, specialist PlGF-based testing can support assessment of suspected preterm pre-eclampsia. Do not delay assessment of a symptomatic patient for the result.

Worked application. At 31 weeks, repeated BP 150/96 mmHg, persistent visual scotomata and newly rising creatinine of 104 µmol/L warrant urgent assessment for pre-eclampsia despite a protein:creatinine ratio of 12 mg/mmol. The creatinine rise and neurological symptoms guide escalation. The protein result alone cannot settle the diagnosis.

ISSHP diagnostic criteria · NICE pregnancy hypertension guidance

Reduce the risk of pre-eclampsia

Placental dysfunction and altered angiogenic signalling contribute to maternal endothelial dysfunction. Placental release of anti-angiogenic factors such as soluble fms-like tyrosine kinase-1 can reduce available VEGF and placental growth factor. This helps explain the combination of hypertension, vascular leakage and multiorgan disease.

Review prevention early in pregnancy. High-risk examples include previous hypertensive disease in pregnancy, chronic hypertension, kidney disease, pre-existing diabetes, SLE or antiphospholipid syndrome. Examples of moderate factors include first pregnancy, older maternal age, a long interval between pregnancies, higher booking BMI, family history and multifetal pregnancy. Apply the risk-factor list and thresholds in the maternity protocol being used.

The 2025 ESC guideline advises 75–150 mg aspirin at bedtime from week 12 to week 36 or 37 for at least one high-risk factor or two moderate factors. The ASPRE trial used 150 mg from 11–14 weeks until 36 weeks in screened high-risk singleton pregnancies. NICE uses 75–150 mg daily from week 12 until birth. Check the local maternity plan for dose, start, stop date and contraindications. Consider calcium intake where dietary intake is low under the applicable guidance.

ESC pregnancy guideline · ASPRE trial · NICE pregnancy hypertension · ISSHP pregnancy hypertension

Treat sustained hypertension and select the agent

Persistent BP of at least 140 mmHg systolic or 90 mmHg diastolic warrants assessment and treatment under the applicable pathway. Choose therapy by the hypertension type, symptoms, comorbidities and prior medicines. The HSE 2026 learning notice cites a target diastolic BP of 85 mmHg and systolic BP below 140 mmHg. Titrate carefully and review symptoms and fetal wellbeing. In mild chronic hypertension, the CHAP trial found improved pregnancy outcomes with a strategy targeting below 140/90 mmHg.

MedicineSelection and safety
Oral labetalolCommon first-line option when suitable. Avoid in patients with asthma or clinically significant bronchospasm and check for bradycardia, heart block or decompensated heart failure.
Modified-release oral nifedipineOption when labetalol is unsuitable, including active asthma. Verify the formulation and product dosing. Avoid sublingual administration. Monitor closely when combining with other agents that can lower BP.
MethyldopaAlternative when other first-line options are unsuitable. Slower onset makes it unsuitable for immediate control of severe BP. Review postpartum therapy and switch away from methyldopa under the local plan.
ACE inhibitors and ARBsAvoid for BP control during pregnancy. Arrange a pregnancy-compatible substitute. Fetal renal dysfunction and oligohydramnios are recognised risks, especially with later exposure. Postpartum choices depend on renal function, potassium and breastfeeding.

HSE 2026 notice · CHAP trial · HPRA labetalol · HPRA prolonged-release nifedipine · NICE drug selection

Match the presentation to the next decision

PresentationImmediate priority
New non-severe hypertension without pre-eclampsia findingsAssess in maternity care, treat sustained hypertension as indicated and monitor for progression.
Pre-eclampsia with severe BP or concerning organ findingsUrgent obstetric and anaesthetic review. Treat severe BP promptly, consider magnesium as indicated, monitor mother and fetus and assess timing of birth.
Eclamptic seizureResuscitate, give IV magnesium, treat severe BP and assess for other causes if indicated. Plan birth after stabilisation if still pregnant.
Suspected HELLPCheck haemolysis, liver enzymes, platelets and coagulation. Stabilise and arrange senior-led expedited birth when indicated.
New severe headache, visual symptoms or hypertension after birthAssess urgently for postpartum pre-eclampsia, eclampsia and other neurological or cardiovascular causes.

Treat acute severe hypertension promptly

Call the senior obstetric and anaesthetic teams. Confirm severe BP promptly and use a monitored setting. Obtain IV access, check maternal oxygenation and assess the fetus as appropriate without delaying maternal resuscitation. The HSE learning notice advises BP checks every 15–30 minutes after treatment until stabilised. During IV titration, follow the more frequent checks in the local emergency protocol.

The Irish Association for Emergency Medicine guidance gives these example emergency regimens. Confirm agent, contraindications, preparation and the local maternity protocol before use.

  • IV labetalol: IAEM gives 50 mg over at least five minutes, with reassessed repeat 50 mg doses at 10-minute intervals up to 200 mg in its bolus protocol. Avoid when asthma, relevant bradycardia or conduction disease makes beta blockade unsuitable.
  • IV hydralazine: IAEM gives 2.5 mg slowly over five minutes and reassesses BP closely, with repeat dosing at 20-minute intervals if needed up to 20 mg. The agent may be used when labetalol is unsuitable. Assess fluid status and avoid routine fluid loading in euvolaemic pre-eclampsia.
  • Oral nifedipine: Some emergency pathways use oral nifedipine if appropriate. Confirm the specific preparation and regimen with the maternity team. Maintenance modified-release dosing is a separate decision. Avoid the sublingual route.

Titrate to take BP out of the severe range promptly and then use the maternity team's stabilisation target. Avoid precipitous falls and reassess for maternal symptoms and fetal compromise. Magnesium is for seizure treatment or prophylaxis when indicated and does not substitute for acute BP control.

IAEM severe pre-eclampsia and eclampsia · HSE Eclampsia Learning Notice · ESC pregnancy guideline

Loading diagram...
Severe Pre-eclampsia, Eclampsia, and Severe Hypertension Algorithm

Treat eclampsia and assess HELLP

Seizure care and magnesium sulphate

A new seizure in pregnancy, labour or the postpartum period can be eclampsia. Call for urgent help. Protect the airway and prevent injury, use left lateral positioning where feasible, check glucose and support oxygenation or ventilation. Evaluate other causes such as epilepsy, hypoglycaemia, infection, venous thrombosis or haemorrhagic stroke as indicated, particularly with focal signs or an atypical course.

IV magnesium sulphate is first line for eclampsia and indicated for seizure prophylaxis in severe pre-eclampsia or relevant neurological symptoms. IAEM uses a 4 g IV loading dose over 5–10 minutes, then 1 g/hour, with continuation for 24 hours after delivery or the last seizure, whichever is later. Use the approved premixed preparation when available and verify concentration and pump settings. For example, a 20 g in 500 mL maintenance bag contains 40 mg/mL and delivers 1 g/hour at 25 mL/hour. For a recurrent seizure, IAEM gives a further 2 g IV and escalation under the emergency protocol. Obtain senior airway and neurological advice if seizures persist.

Monitor respiration, oxygenation, deep tendon reflexes and urine output. Oliguria and renal impairment increase the risk of accumulation. Review magnesium concentrations, formulation and maintenance dosing with the maternity and critical-care teams in this setting. A low respiratory rate, absent reflexes and oliguria together strongly suggest toxicity. Stop the infusion and support ventilation immediately. Give 10 mL of 10% calcium gluconate by slow IV injection, with monitoring and under the local protocol. This is the obstetric magnesium-antagonism dose. Severe hyperkalaemic ECG toxicity uses a separate regimen.

HELLP, delivery and follow-up

HELLP combines haemolysis, elevated liver enzymes and low platelets. Look for fragmented red cells or other haemolysis evidence alongside liver enzymes and platelet trends. LDH can rise for several reasons and does not establish haemolysis by itself. Epigastric or right upper quadrant pain, nausea or malaise may be prominent. Consider abruption, DIC, acute kidney injury and hepatic haematoma or rupture when indicated, and alternative diagnoses such as acute fatty liver of pregnancy or another thrombotic microangiopathy.

Stabilise the mother, treat severe BP and give magnesium when indicated. Obtain senior obstetric, anaesthetic and neonatal input. Persistent neurological symptoms, eclampsia, worsening organ dysfunction or fetal compromise can require birth before term. HELLP usually warrants expedited birth after stabilisation. Choose mode of birth according to urgency, fetal status, cervical findings and other obstetric factors. Plan platelets and other blood products with the team based on bleeding, count and trend, coagulation and procedure. Consider antenatal corticosteroids for fetal benefit when appropriate without delaying necessary birth.

Continue surveillance after birth because BP, symptoms and laboratory abnormalities can worsen initially. Arrange postpartum BP monitoring and review of persistent hypertension or proteinuria. Discuss recurrence risk and longer-term cardiovascular follow-up.

IAEM magnesium and eclampsia guidance · HSE pre-eclampsia guidance · Magpie trial · ISSHP delivery and postpartum guidance · EASL liver disease in pregnancy guideline

Test Your Knowledge

A 34-year-old primigravida at 32 weeks gestation is admitted with a 2-day history of persistent fronto-occipital headache and visual blurring. Her blood pressure is 168/114 mmHg and remains in the severe range on prompt repeat. She has no asthma or other contraindication to labetalol. Urinalysis demonstrates 3+ protein, and laboratory investigations confirm: platelets 84 x 10^9/L, serum creatinine 112 mcmol/L, AST 145 U/L, and LDH 780 U/L. Her blood film shows schistocytes and haptoglobin is low. Fetal ultrasound demonstrates an active fetus with normal fluid and biophysical profile. What is the most appropriate immediate medical management?

A

Commence oral labetalol 100 mg twice daily and schedule an elective induction of labour at 37 weeks

B

Administer oral ramipril 5 mg once daily and start an intravenous diazepam infusion for seizure prophylaxis

C

Perform immediate emergency caesarean delivery under general anaesthesia without prior medical stabilization

D

Treat severe BP with IV labetalol under the emergency protocol, give IV magnesium sulphate with renal and clinical monitoring, and plan expedited birth after stabilisation.

Test Your Knowledge

A 29-year-old gravida 2 para 1 at 35 weeks gestation with known severe pre-eclampsia is receiving a continuous intravenous magnesium sulphate infusion (1 g/hour) following an initial 4 g loading infusion. Four hours into the infusion, routine nursing monitoring reveals: blood pressure 142/88 mmHg, heart rate 82 bpm, respiratory rate 9 breaths/min, oxygen saturation 93% on room air, and patellar deep tendon reflexes are completely absent bilaterally. Urine output over the preceding 2 hours was 18 mL total. What is the most appropriate immediate intervention?

A

Stop magnesium sulphate, call for immediate ventilatory support and give 10 mL of 10% calcium gluconate by slow IV injection.

B

Increase the intravenous magnesium sulphate infusion rate to 2 g/hour to treat recurrent eclampsia

C

Administer intravenous naloxone 400 mcg and transfer the patient to the intensive care unit

D

Infuse a 1,000 mL bolus of 0.9% normal saline over 15 minutes to treat the oliguria

Test Your Knowledge

A 32-year-old woman with a history of moderate-to-severe persistent asthma requiring a daily inhaled corticosteroid and long-acting beta-agonist attends the antenatal clinic at 28 weeks gestation. Her blood pressure is recorded at 154/98 mmHg on two measurements taken 4 hours apart. She was normotensive before 20 weeks. Her urine protein:creatinine ratio is 14 mg/mmol and her other investigations and fetal assessment show no features of pre-eclampsia. Which antihypertensive medication is the most appropriate first-line choice for this patient?

A

Oral labetalol

B

Modified-release oral nifedipine

C

Oral enalapril

D

Oral losartan

Sections you finish are checked off in the contents.